Human placental ribonuclease inhibitor (PRI) abolishes both the ribonucleolytic activity of angiogenin toward 28S and 18S rRNA and its angiogenic activity on the chicken embryo chorioallantoic membrane. Treatment of the angiogenin-PRI complex with p-hydroxymercuribenzoate releases enzymatically active angiogenin. Assays measuring competition between angiogenin and bovine pancreatic ribonuclease A for PRI reveal that binding of the inhibitor to angiogenin is extremely tight, with aKi value well below 0.1 nM. The stability of the angiogenin-PRI complex was assessed by cation-exchange HPLC quantitation of free angiogenin. No significant dissociation was detected after 17 hr at 25°C in the presence of a large excess of bovine ribonuclease, which serves as a scavenger for free inhibitor. The results of these experiments, based on the predictive capacity of the angiogenin/RNase homology, suggest that PRI and related inhibitors may participate in the in vivo regulation ofangiogenin and that this might have pharmacologic and/or therapeutic implications.
of the angiogenin-PRI complex was assessed by cation-exchange HPLC quantitation of free angiogenin. No significant dissociation was detected after 17 hr at 25°C in the presence of a large excess of bovine ribonuclease, which serves as a scavenger for free inhibitor. The results of these experiments, based on the predictive capacity of the angiogenin/RNase homology, suggest that PRI and related inhibitors may participate in the in vivo regulation ofangiogenin and that this might have pharmacologic and/or therapeutic implications.
The primary structure of angiogenin, a blood vessel-inducing protein from HT-29 human colon adenocarcinoma cells (1) , is highly homologous to that of the pancreatic ribonucleases (RNases) (2, 3) . Indeed, angiogenin exhibits ribonucleolytic activity, but its specificity differs distinctly from that of pancreatic RNase (4) . Angiogenin catalyzes the limited cleavage of 28S and 18S rRNA; the resultant-products are 100-500 nucleotides long. It does not exhibit significant activity in any of the standard pancreatic RNase assays that were examined (4) .
From the point of view of protein chemistry, the mechanism of action of angiogenin-or, for that matter, ofany other blood vessel-inducing protein-is not yet known. In this regard, however, its homology with RNase is most fortunate. It provides an excellent opportunity to benefit from the extensive detailed knowledge of RNase already on record, as well as a means to bypass conventional approaches to assess structure-function relationships. The predictive capacity of this knowledge encompasses (i) catalytically essential amino acid residues that might serve as mutagenic targets, (ii) specific reagents for chemical modification, and (iii) most pertinent to the present discussion, the potential of selective inhibitors.
Potent pancreatic RNase inhibitors have long been known to be present in mammalian tissues (see refs. 5 and 6 for reviews). One of these, isolated from human placenta, has been studied most extensively. It is an acid-labile, sulfhydryldependent protein with a molecular mass of 51,000 daltons.
It is reported to bind to bovine pancreatic RNase A with a Ki of 0.3 nM (7) . Human placental RNase inhibitor (PRI) has now been found to abolish both the biological and the enzymatic activities of angiogenin, thus further confirming that the angiogenin/RNase homology is functionally significant.
MATERIALS AND METHODS
Angiogenin was purified to homogeneity as described (1, 4) or by procedures to be published elsewhere. Human PRI was isolated by the method of Blackburn (8) . Bovine pancreatic RNase A was a product of Cooper Biomedical (Malvern, PA). Calf liver rRNA (28S and 18S) was purchased from Pharmacia, and p-hydroxymercuribenzoate (pHMB), uridylyl(3',5')adenosine (UpA), hen egg white lysozyme, and human serum albumin (HSA) were obtained from Sigma.
Angiogenin and RNase A concentrations were determined as described (4) . PRI concentrations were measured by titration with RNase A (8) . RNase A activity toward UpA was measured spectrophotometrically (9) . Assay mixtures contained 0.2 mM dinucleotide, 1 mM EDTA, and 10 ,ug of HSA per ml in 0.1 M Mes/0.1 M NaCl, pH 6. The decrease in absorbance at 280 nm was continuously monitored at 250C with a Gilford model 250 spectrophotometer.
Activity of angiogenin toward rRNA was measured as described (4) . Angiogenesis activity was assessed by a modification (1) of the chicken embryo chorioallantoic membrane assay of Knighton et al. (10) . PRI used in chorioallantoic membrane assays was desalted in a Centricon-10 microconcentrator (Amicon). Inhibitor [stored in either 20 mM Tris/150 mM NaCl, pH 7.5, or 100 mM sodium acetate/3 M NaCl, pH 5.0, in both cases containing 1 mM EDTA, 5 mM dithiothreitol, and 15% (vol/vol) glycerol] was added to sterile deionized water that had been degassed and then saturated with nitrogen. This solution was concentrated by centrifugation in the microconcentrator according to the manufacturer's instructions. Inhibitor prepared by this procedure was fully active in the assay of Blackburn (8) .
Carboxymethyl cation-exchange HPLC was performed with a Synchropak CM300 column (250 x 4.1 mm; SynChrom, Linden, IN), utilizing a Waters Associates liquid chromatography system in conjunction with a HewlettPackard 3390A integrator. Elution was achieved with a 10-min linear gradient from 220 to 620 mM NaCl in 20 mM sodium phosphate (pH 7.0) at a flow rate of 1.0 ml/min at ambient temperature. Column effluents were monitored at 214 nm.
RESULTS
Inhibition of Ribonucleolytic Activity of Angiogenin by PRI.
Angiogenin catalyzes the cleavage of both 28S and 18S rRNA, forming characteristic products that are 100-500 nucleotides in length (Fig. 1, lane 2) . Addition of 1.2 molar equivalents of PRI to angiogenin completely inhibits this Abbreviations: PRI, human placental ribonuclease inhibitor; pHMB, p-hydroxymercuribenzoate; UpA, uridylyl(3',5')adenosine; HSA, human serum albumin.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. and inactive PRI (7), the dissociability of the angiogenin-PRI complex was similarly tested with pHMB. The formation of free angiogenin was monitored by cation-exchange HPLC. A peak was eluted at the same time as native angiogenin, indicating that pHMB indeed releases angiogenin from the complex. Untreated complex remains intact during the course of the HPLC procedure and is eluted well before angiogenin (see below). The amount of angiogenin recovered represents 70% of that added initially and has full enzymatic activity (Fig. 1, lane 5) .
Competition Between Angiogenin and RNase A for PRI. The competition between angiogenin and RNase A for the placental inhibitor was examined by means of an enzymatic assay. The dinucleotide UpA is not cleaved by angiogenin at a detectable rate (4), but it is an excellent substrate for RNase A. Therefore it was used to assess the partitioning of PRI between the two proteins. The activity measured reveals directly the amount of RNase A not bound to PRI. Assay mixtures contained various amounts of angiogenin, 0.27 nM RNase A, and 0.20 nM PRI. The RNase A and angiogenin were added to the assay buffer first, and the mixture was preincubated with inhibitor for 5 min at 250C. The enzymatic reaction was then initiated by addition of substrate.
The amount of PRI employed is sufficient to inhibit 70% of the potential RNase A activity. When angiogenin is present it binds to PRI, which is therefore unavailable to inhibit RNase A. Hence, increasing concentrations of angiogenin progressively decrease RNase inhibition; at 5.8 nM angiogenin there is essentially no inhibition at all (Fig. 2) . Lysozyme (40 nM) closely similar to both angiogenin and RNase in size and basicity, has no effect.
These competition assays examine the relative degrees of binding of PRI to angiogenin and RNase A upon addition of the inhibitor to a mixture of the two enzymes (see Discussion). An estimate of the Ki value for binding of PRI to angiogenin was obtained by a modified procedure in which PRI and angiogenin were preincubated for 10 min, followed by addition of RNase A and measurement of UpA cleavage. Since dissociation of the PRI-angiogenin complex is extremely slow (see below), this assay determines the amount of free inhibitor remaining after incubation of PRI with angiogenin alone. At an angiogenin/PRI ratio of 1.2, there is no detectable PRI inhibition of RNase activity-i.e., no free PRI. Thus, all of the PRI must be complexed to angiogenin (4) . activity (Fig. 1, lane 3) . Since 17 (12) Angiogenin + PRI 15 (26) 25 (52) 7 (14) Assays were performed on chicken embryo chorioallantoic membrane as described (1 (5, 6) . Purified preparations of such inhibitors from human placenta (7), bovine brain (11), and porcine thyroid and liver (12) inhibit bovine RNase A with subnanomolar Ki values, making them by far the most potent known inhibitors of this enzyme. These proteins have also proved to be effective inhibitors of non-pancreatic intracellular RNases; as a result, it has recently become customary to use them as reagents to increase yields of higher molecular weight proteins in in vitro translation systems (13) and improve the quality of RNA isolated from tissue homogenates (14) . Hence, the in vivo role of these inhibitors has been thought to be related to control of mRNA turnover and, thus, protein synthesis (15) .
The primary sequence of angiogenin is highly homologous to that of pancreatic RNase (2, 3). In fact, angiogenin is a ribonucleolytic enzyme (4) . We have therefore examined its interaction with the human placental RNase inhibitor (PRI).
Originally isolated from medium conditioned by human tumor cells, angiogenin is not a tumor-specific protein: it has been detected in a variety of other sources, where it likely plays a role in normal and/or pathologicalneovascularization. If inhibitors such as PRI were to interact strongly with angiogenin, this might represent a hitherto unsuspected function for them: regulation of angiogenesis. Moreover, this could lead to avenues of exploration for the management of various pathological conditions characterized by or dependent on abnormal neovascularization.
PRI is indeed a potent antagonist of both the angiogenic and ribonucleolytic activities of angiogenin. As with bovine pancreatic RNase A (6), this inhibition is reversible, and the complex can be readily dissociated by addition of p1MB to yield angiogenin that is active and chromatographically identical to the native protein. The stoichiometry of the interaction is 1:1; a slight molar excess of PRI is sufficient to inhibit enzymatic activity completely (Fig. 1) .
Specific substrates of angiogenin have not been identified as yet, and since our present assay system for the measurement of its ribonucleolytic activity (4) The competition experiments also provide information concerning the relative affinities of PRI for angiogenin vs. RNase A. When PRI is added to a mixture of angiogenin and RNase A, equal concentrations of the angiogenin-PRI and RNase A-PRI complexes are formed at a total angiogenin concentration twice that of total RNase A (Fig. 2) . Under these conditions the concentrations of free angiogenin and RNase A are calculated to be 0.48 and 0.17 nM, respectively. If this assay mixture were at equilibrium, these results would indicate that the Ki value of PRI for angiogenin is 2.8-fold higher than that for RNase A. However, data obtained by HPLC for angiogenin (cited above) and for RNase A show that this is not an equilibrium situation, since the dissociation rates for both complexes with PRI are extremely slow. Thus, the partitioning of inhibitor between angiogenin and RNase more likely reflects the relative rates of association rather than the relative Ki values.
Blackburn and coworkers (6, (16) (17) (18) have studied the structural basis for the interaction between PRI and RNase A by means of proteolytic and chemical modifications and found that carboxymethylation of Lys-41 of RNase A substantially reduces binding strength, indicating an important role for this residue. They further suggested three contact regions for PRI in the three-dimensional structure of RNase A: the areas containing (i) Lys-7, Lys-41, Pro-42, Val-43, Lys-91, Tyr-92, and Pro-93; (ih) Lys-31 and -37; and (iii) Lys-61 and adjacent residues. In these regions angiogenin and RNase A are remarkably similar, with identical residues at positions corresponding to Lys-41, Pro-93, Lys-61, and Asn-62 and similar residues at positions corresponding to Lys-7 (His), Val-43 (Ile), Tyr-92 (Trp), Lys-31 (Arg), and Gln-60 (Asn). Hence, both proteins might be expected to bind PRI with comparable avidity. Indeed, the strength of the angiogenin-PRI interaction provides experimental support that the overall three-dimensional structures of angiogenin and pancreatic RNase are closely similar, as already suggested by energy-minimization procedures (19) .
The establishment of the chemical structure of angiogenin and the detection of its extensive homology with pancreatic RNase were critical in recognizing that PRI is a powerful inhibitor of angiogenin. This inhibition affects both the biological and enzymatic activities of angiogenin and may have important mechanistic, physiologic, and pharmacologic implications. It is consistent with the hypothesis that these two actions of angiogenin are interrelated, as suggested previously by the simultaneous loss of both activities upon carboxymethylation by bromoacetate at pH 5.5 (4). Further, it raises the possibility that PRI may play a role in the in vivo regulation of angiogenin. As noted above, the angiogenin-PRI interaction likely involves regions of angiogenin that are separated widely in the three-dimensional structure, many of them outside the active center. Thus, conservation of residues necessary for enzymatic activity alone probably cannot account for the strength of the interaction. This implies that the capacity of angiogenin to bind PRI has been maintained independently during evolution. It would therefore seem plausible that binding by PRI and related inhibitors reflects a physiologically relevant control mechanism that might have pharmacologic and therapeutic potential.
